Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Karyopharm Therapeutics
About
Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.
- Newton,Massachusetts,United States
- 251 - 500
- http://www.karyopharm.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $165M
- Industries
- Health Care,Medical,Pharmaceutical
- Founded date
- Jan 1, 2008
- Number Of Employee
- 251 - 500
- Operating Status
- Active
- Stock Symbol
- nasdaq:KPTI
- Legal Name
- Karyopharm Therapeutics Inc.
- Also Known As
- Karyopharm
Karyopharm Therapeutics is a biopharmaceutical company with a focus on the development of novel drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g. FOXO, NFкB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and evaluate them in subsequent human clinical studies.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 5, 2022 | Post-IPO Equity | $165M | 9 |
Avidity Partners
|
— | Detail |
| Mar 6, 2020 | Post-IPO Equity | $172.50M | — | — | — | Detail |
| Jun 30, 2014 | Post-IPO Equity | $111M | — | — | — | Detail |
| Nov 6, 2013 | IPO | $108.80M | — | — | — | Detail |
| Jul 31, 2013 | Series B | $19M | 3 |
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Avidity Partners
|
Yes | Post-IPO Equity |
|
|
Yes | Series B |
|
|
Yes | Series A |
Multiple Myeloma Research Foundation
|
Yes | Grant |
Adage Capital Management
|
— | Post-IPO Equity |
|
|
— | Post-IPO Equity |
HealthCor Partners
|
— | Post-IPO Equity |
Heights Capital Management
|
— | Post-IPO Equity |
Marshall Wace
|
— | Post-IPO Equity |
Rubric Capital Management
|
— | Post-IPO Equity |
Employee Profiles
